---
schema_version: "secwatch.filing_event.v1"
accession: "0001090872-24-000045"
form_type: "8-K"
ticker: "A"
cik: "0001090872"
company_name: "AGILENT TECHNOLOGIES, INC."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:17:33.162591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Agilent reorganizes into three reportable segments: LSD, Applied, CrossLab

## Summary
- New segments: Life Sciences & Diagnostics Markets, Applied Markets, Agilent CrossLab, effective FY2025.
- FY24 segment revenue: LSD $2,466M, CrossLab $2,747M, Applied $1,297M; operating margins 19.6%, 33.7%, 24.0%.
- FY23 segment revenue: LSD $2,780M, CrossLab $2,656M, Applied $1,397M; LSD operating margin dropped from 24.2% to 19.6%.
- Historical unaudited segment data provided for FY22, FY23, FY24; prior periods will be recast going forward.
- No change to previously reported consolidated results; reorganization is market-focused, customer-centric.

## SEC filing metadata
- accession: 0001090872-24-000045
- form_type: 8-K
- ticker: A
- cik: 0001090872
- company_name: AGILENT TECHNOLOGIES, INC.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1090872/000109087224000045/0001090872-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1090872/000109087224000045/a-20241213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001090872-24-000045
- JSON: https://secwatch.observer/filing/0001090872-24-000045.json
- Plain text: https://secwatch.observer/filing/0001090872-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.